Fortress Biotech Inc Pref Series A (FBIOP)
Fortress Biotech Inc Pref Series A (FBIO.P) is a preferred stock listed on NASDAQ and associated with Fortress Biotech, Inc., a biopharmaceutical company based in Bay Harbor Islands, Florida. Fortress Biotech focuses on the development and commercialization of pharmaceutical products across several therapeutic areas, including dermatology, oncology, rare diseases, and infectious disease research. Its portfolio includes marketed products such as Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend, alongside a pipeline of clinical, early-stage, and preclinical candidates. These include programs such as intravenous Tramadol, CUTX-101, UNLOXCYT, Olafertinib, CAEL-101, Triplex, and multiple additional development assets. The company was incorporated in 2006 and adopted its current name in 2015.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-FBIO.P
|
$15.39
|
-17.5% Downside
|
Fair
|
—
|
—
|
—
|
Great
|
—
|
—
|
—
|
0.0%
|
August 13, 2026
|
1.0x
|
0.7x
|
1.8x
|
110.6 M
|
-45.446 M
|
26.2%
|
69.5%
|
1.2
|
—
|
132.2%
|
